Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 48 (RPL23AP48) is a processed pseudogene in the human genome, one of many non-coding sequences related to the protein-coding RPL23A gene, which encodes the 60S ribosomal protein L23a involved in ribosomal function and protein synthesis. RPL23AP48 does not code for a functional protein and has no known biological or pathological activity. There are over 90 such pseudogenes for RPL23A in the human genome, and their potential regulatory or evolutionary impact is unclear, though some ribosomal protein pseudogenes have been researched for possible roles as non-coding RNAs in certain contexts. However, there is no evidence that RPL23AP48 itself is a functional therapeutic target, marker, or has any role in disease[3][4][6][8]. Most studies and resources do not attribute any biological activity, clinical targetability, or disease relevance to RPL23AP48. The protein-coding gene RPL23A (not the pseudogene) has been studied for roles in protein synthesis and cancer, but RPL23A pseudogenes (including RPL23AP48) remain largely uncharacterized, with no indication of physiological or pathological function for this specific entry[3][5][6][8]. If you are seeking information on a functional therapeutic target, this entity does not meet that criterion. If your focus is instead on non-coding RNAs or pseudogenes with potential regulatory roles, other pseudogenes (e.g., RPL23AP53) have been under research scrutiny, but no such information exists for RPL23AP48 specifically[2].
None (no drugs interact with this pseudogene)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 48 (RPL23AP48).